Acarix AB (publ) publishes Interim Report, January – June 2020

For us and for many other companies, the pandemic and global uncertainty have caused delays in some
prioritized projects. However, in combination with a dynamic capital market this has created a window
for us to review our overall funding. The opportunity to secure funding will enable full focus with
continued commercialization in priority markets and continued the research as soon as the market is
normalized again.

Acarix Interim report Q2 2020

Acarix Delårsrapport Q2 2020

About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, is Certified Advisor of Acarix.

For more information, please visit